

IN THE CLAIMS:

1. – 8. (Canceled)

9. (Currently amended) The lipopeptide according to claim [[8]] 37 wherein ~~the lipopeptide moiety~~ Z is Pam₂Cys.

10. – 14. (Canceled)

15. (Currently amended) The lipopeptide of claim [[1]] 34 wherein the T-helper epitope is a T-helper epitope of influenza virus haemagglutinin or a T-helper epitope of canine distemper virus F (CDV-F) protein.

16. (Original) The lipopeptide of claim 15 wherein the T-helper epitope of influenza virus haemagglutinin comprises the amino acid sequence set forth in SEQ ID NO: 1.

17. (Original) The lipopeptide of claim 15 wherein the T-helper epitope of CDV-F protein comprises the amino acid sequence set forth in SEQ ID NO: 20.

18. (Currently amended) The lipopeptide of claim [[1]] 34 wherein the CTL epitope is from an immunogenic protein, lipoprotein, or glycoprotein of a virus.

19. (Original) The lipopeptide according to claim 18 wherein the virus is influenza virus.

20. (Original) The lipopeptide of claim 19 wherein the CTL epitope comprises the amino acid sequence set forth in SEQ ID NO: 2.

21. (Original) The lipopeptide according to claim 18 wherein the virus is hepatitis C virus.

22. (Original) The lipopeptide of claim 21 wherein the CTL epitope comprises the amino acid sequence set forth in SEQ ID NO: 176.

23. **(Currently amended)** The lipopeptide of claim [[1]] 34 wherein the CTL epitope is from an immunogenic protein, lipoprotein, or glycoprotein of a prokaryotic organism.

24. **(Original)** The lipopeptide according to claim 23 wherein the CTL epitope is from *Listeria monocytogenes*.

25. **(Original)** The lipopeptide of claim 24 wherein the CTL epitope comprises the amino acid sequence set forth in SEQ ID NO: 172.

26. **(Currently amended)** The lipopeptide of claim [[1]] 34 wherein the CTL epitope is from an immunogenic protein, lipoprotein, or glycoprotein of a eukaryotic organism.

27. **(Original)** The lipopeptide according claim 26 wherein the eukaryotic organism is a parasite.

28. **(Original)** The lipopeptide according to claim 26 wherein the eukaryotic organism is a mammal.

29. **(Original)** The lipopeptide according to claim 28 wherein the CTL epitope is from an ovalbumin protein of a mammal or a tumor cell.

30. **(Original)** The lipopeptide according to claim 29 wherein the CTL epitope comprises the amino acid sequence set forth in SEQ ID NO: 173.

31. – 33. **(Canceled)**


34. **(Previously Presented)** A lipopeptide comprising a polypeptide conjugated to one or more lipid moieties wherein:

(i) said polypeptide comprises an amino acid sequence that comprises:

(a) the amino acid sequence of a T helper cell (Th) epitope and the amino acid sequence of a CTL epitope, wherein said amino acid sequences are different; and

- (b) one or more internal lysine or lysine analogue residues for covalent attachment of each of said lipid moieties via the epsilon-amino group of said one or more lysine or lysine analogue residues;
- (ii) each of said one or more lipid moieties is covalently attached to an epsilon-amino group of said one or more internal lysine residues; and
- (iii) said lipopeptide has the general Formula (VI):

Formula (VI):



wherein:

epitope is a T-helper epitope or CTL epitope;

- A is either present or absent and consists of an amino acid spacer of about 1 to about 6 amino acids in length;
- n is an integer having a value of 1, 2, 3, or 4;
- X is a terminal side-chain group selected from the group consisting of NH, O and S;
- Y is either present or absent and consists of an amino acid spacer of about 1 to about 6 amino acids in length; and
- Z is a lipid moiety.

35. **(Original)** The lipopeptide of claim 34 wherein A is absent.

36. **(Previously Presented)** The lipopeptide of claim 34 wherein Y is present and consists of a serine homodimer.

37. **(Previously Presented)** The lipopeptide of claim 34 wherein Z is selected from the group consisting of: Pam₁Cys, Pam₂Cys, Pam₃Cys, Chol₂Lys, Ste₂Cys, Lau₂Cys, and Oct₂Cys.

38. **(Previously Presented)** The lipopeptide of claim 34 capable of upregulating the surface expression of MHC class II molecules on immature dendritic cells (DC).

39. **(Original)** The lipopeptide of claim 38 wherein the DC are D1 cells.

40. - 51. **(Canceled)**

52. **(Currently amended)** A composition comprising the lipopeptide of claim [[1]] 34 and a pharmaceutically acceptable excipient or diluent.

53. **(Original)** The composition of claim 52 further comprising a biologic response modifier (BRM).

54. **(Currently amended)** A method of eliciting an immune response in a subject comprising administering the lipopeptide of claim [[1]] 34 to said subject for a time and under conditions sufficient to elicit a cytotoxic T cell response against a CTL epitope in the lipopeptide.

55. **(Original)** The method according to claim 54 wherein the lipopeptide is administered intranasally to the subject.

56. **(Original)** The method according to claim 54 wherein the lipopeptide is administered to the subject by injection.

57. – 65. **(Canceled)**

66. **(Currently amended)** A vaccine against an influenza virus comprising the lipopeptide of claim [[1]] 34 wherein the CTL epitope is from an influenza virus protein.

67. – 76. (Canceled)

77. (Currently amended) A vaccine against a hepatitis C virus comprising the lipopeptide of claim [[1]] 34 wherein the CTL epitope is from a hepatitis C virus protein.

78. – 87. (Canceled)

88. (Currently amended) A vaccine against *Listeria monocytogenes* comprising the lipopeptide of claim [[1]] 34 wherein the CTL epitope is from a *Listeria monocytogenes* protein.

89. – 98. (Canceled)

99. (Currently amended) A prophylactic or therapeutic vaccine against cancer comprising the lipopeptide of claim [[1]] 34 wherein the CTL epitope is a tumor-specific CTL epitope.

100. (Canceled)